Full Press Release Details
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 8, 2025, at 7:00 a.m. ET during the 67thAmerican Society of Hematology (ASH) Annual Meeting. Members of the Syndax management team will be joined by multiple key opinion leaders to discuss data updates from the Company’s Revuforj®(revumenib) and Niktimvo™ (axatilimab-csfr) programs.
A live webcast of the event will be available on the Investor section of the Company's website atwww.syndax.com, where a replay of the event will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj®(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visitwww.syndax.comor follow the Company onXandLinkedIn.
Syndax Contacts
Sharon KlahreSyndax Pharmaceuticals, Inc.sklahre@syndax.comTel 781.684.9827
SNDX-G